Astellas Tacrolimus Approval Remains At Bay
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma has met with another snag in its attempt to win FDA approval for the once-daily version of its immunosuppressant Prograf (tacrolimus) with receipt of an FDA "approvable" letter for prophylaxis of organ rejection in liver transplant patients